SBFM — Sunshine Biopharma Share Price
0.000.00%
Last trade - 00:00- $5.49m
- -$4.18m
- $34.87m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.23 | ||
| Price to Tang. Book | 0.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.16 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.97% | ||
| Return on Equity | -22.97% | ||
| Operating Margin | -16.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.07 | 0.23 | 4.35 | 24.09 | 34.87 | 100 | n/a | 340.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Directors
- Steve Slilaty CHM (68)
- Camille Sebaaly CFO (60)
- Abderrazzak Merzouki COO (57)
- Rabi Kiderchah IND (49)
- James Kish IND (67)
- Andrew Telsey IND (67)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 31st, 2006
- Public Since
- August 15th, 2008
- No. of Shareholders
- 149
- No. of Employees
- 52
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,635,945
- Address
- 333 Las Olas Way, Cu4 Suite 433, FORT LAUDERDALE, 33301
- Web
- https://www.sunshinebiopharma.com/
- Phone
- +1 9545150810
- Auditors
- Bush & Associates CPA LLC
Upcoming Events for SBFM
Q2 2025 Sunshine Biopharma Inc Earnings Release
Similar to SBFM
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Sunshine Biopharma share price?
As of Today at 23:30 UTC, shares in Sunshine Biopharma are trading at $1.51. This share price information is delayed by 15 minutes.
How has the Sunshine Biopharma share price performed this year?
Shares in Sunshine Biopharma last closed at $1.51 and the price had moved by -90.65% over the past 365 days. In terms of relative price strength the Sunshine Biopharma share price has underperformed the S&P500 Index by -91.37% over the past year.
What are the analyst and broker recommendations for Sunshine Biopharma?
The overall consensus recommendation for Sunshine Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sunshine Biopharma dividend yield?
Sunshine Biopharma does not currently pay a dividend.
Does Sunshine Biopharma pay a dividend?
Sunshine Biopharma does not currently pay a dividend.
When does Sunshine Biopharma next pay dividends?
Sunshine Biopharma does not currently pay a dividend.
How do I buy Sunshine Biopharma shares?
To buy shares in Sunshine Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sunshine Biopharma?
As of the previous close price of $1.51, shares in Sunshine Biopharma had a market capitalisation of $5.49m.
Where are Sunshine Biopharma shares listed?
Here are the trading details for Sunshine Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SBFM
What kind of share is Sunshine Biopharma?
Based on an overall assessment of its quality, value and momentum Sunshine Biopharma is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sunshine Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Sunshine Biopharma is $300.00. That is 19767.55% above the last closing price of $1.51.
Analysts covering Sunshine Biopharma currently have a consensus Earnings Per Share (EPS) forecast of $0.74 for the next financial year.
Find out moreWhat is the trend in the Sunshine Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sunshine Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -47.3%.
As of the last closing price of $1.51, shares in Sunshine Biopharma were trading -48.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sunshine Biopharma PE Ratio?
The Sunshine Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sunshine Biopharma?
Sunshine Biopharma's management team is headed by:
- Steve Slilaty - CHM
- Camille Sebaaly - CFO
- Abderrazzak Merzouki - COO
- Rabi Kiderchah - IND
- James Kish - IND
- Andrew Telsey - IND